Marina Díaz-Beyá, Myriam Labopin, Johan Maertens, Mahmoud Aljurf, Jakob Passweg, Beelen Dietrich, Harry Schouten, Gerard Socié, Nicolaas Schaap, Rainer Schwerdtfeger, Liisa Volin, Mauricette Michallet, Emmanuelle Polge, Jorge Sierra, Mohamad Mohty, Jordi Esteve, Arnon Nagler
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001)...
June 2020: British Journal of Haematology